Comparing the Quality of Life of Terminal Ileitis Patients With Crohn's Disease Treated With Anti-TNF or Surgical Resection

Quality of Life Clinical Trial

— CASINO  

Official title:

Comparing the Quality of Life of Terminal Ileitis Patients With Crohn's Disease Treated With Anti-TNF or Surgical Resection

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02872506
• Other study ID #: 2015_19
• Secondary ID: 2016-A00019-42
• Status: Withdrawn
• Phase: N/A
• Start date: September 2017
• Est. completion date: August 2018

Study information

• Verified date: October 2018
• Source: University Hospital, Lille
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Compare the quality of life at 6 months between 2 populations of patients followed for terminal ileitis of Crohn's disease treated with anti-TNF or ileocecal resection.

Description:

Two groups of patients suffering from Crohn's terminal ileitis will be matched by sex, age (A2, A3), the time evolution of the disease, the length of the diseased ileal segment (less than 10 cm; 10 to 30; 30 to 50 cm) and the Montreal classification (B1, B2). The medical treatment group will be chosen among patients receiving anti-TNF therapy for the first time. The surgical group are the patients operated on for the first time by means of ileocecal resection by laparoscopy or laparotomy without any severity criteria or perianal lesions and do not require prophylactic treatment of recurrence.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: August 2018
• Est. primary completion date: August 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• isolated Crohn's ileitis without history of bowel resection and never previously been treated with anti-TNF

• Men and woman over 18 years

• Patient with social security cover

• reapproved indication during multidisciplinary meeting

• Patient able to receive clear information in written and oral

• Informed consent signed by the patient

Exclusion Criteria:

• Prophylactic treatment of recurrence before endoscopic control at the 6th postoperative month.

• Contraindication to Anti-TNF after the initial lap works.

• The side effects of surgery or anti-TNF are not exclusion criteria.

Related Conditions & MeSH terms

• Crohn Disease
• Ileitis
• Quality of Life

Intervention

Drug:
• Anti TNF
Patients are admitted to day hospital with blood test less than 7 days. In the absence of contraindications, hydrocortisone infusion 200 mg will be conducted for 15 minutes followed by anti-TNF treatment infusion over 2 hours for the first three sessions. The following infusions of anti-TNF therapy will be on the same terms without hydrocortisone, every 4 to 8 weeks, in doses of 5-10mg/kg. Adverse effect most frequently reported was URTI. The most serious adverse reactions, were a reactivation of hepatitis B, congestive heart failure, serious infection, serum hypersensitivity reactions, blood diseases, systemic lupus erythematosus / lupus-like syndrome, demyelinating disorders, hepatobiliary metabolism disorders. The QOL will be assessed by IBDQ score at the inclusion visit before the first infusion and at 6 months.

Procedure:
• ileocecal resection
The operation is performed by laparoscopy or laparotomy. Hospital stay is on average 6 days. Preparation for the intervention is sometimes required 3 weeks to 1 month before the procedure to avoid risk situations.The main risk of the intervention is the anastomotic fistula. This risk of anastomotic leakage mainly concerns malnourished patients operated within the context of abdominal sepsis (abscess). An assessment protocol of post-operative pain, every 3 hours, is now well codified in routine surgery. The QOL will be assessed by the IBDQ score before surgery and at 6 months.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Lille

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	quality of life (QoL) by Inflammatory Bowel Disease Questionnaire	comparing the quality of life (QoL) by Inflammatory Bowel Disease Questionnaire (IBDQ) at 6 months between 2 populations of patients followed for Crohn's terminal ileitis treated with anti-TNF or operated on by means of ileocecal resection	at 6 months from the beginning of medical treatment or surgical resection
Secondary	Inflammatory Bowel Disease Questionnaire (IBDQ)	Inflammatory Bowel Disease Questionnaire (IBDQ) at 6 months between 2 populations of patient	at baseline (beginning of medical treatment or surgical resection), at 6 months
Secondary	Crohn's disease activity index (CDAI)		at baseline, at 6 months
Secondary	Length of small intestine segment resection	Length of small intestine segment <10 cm 10 to 30 cm 30 to 50 cm	at baseline
Secondary	Duration of hospital stay		at baseline
Secondary	Clavien-Dindo classification of surgical complications		at baseline, at 6 months